Clinical Trial Update: Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

View source ↗

Summary

The document notes marketing approval for TMC207 (bedaquiline) to treat extensively drug-resistant or pre-XDR pulmonary tuberculosis through an early access/mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensively Drug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• TMC207 (bedaquiline)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Tuberculosis | Status: APPROVED_FOR_MARKETING